Mirion Technologies, Inc. — FY 2022 Form 10-K
Business context and reporting period. Mirion supplies radiation detection, measurement, monitoring, software and services for medical and industrial markets, including nuclear energy, defense, laboratories and research. This 10-K covers the fiscal year ended December 31, 2022, not standalone fourth-quarter results. The company changed its year-end from June 30 and completed its business combination on October 20, 2021; acquisition accounting created a stepped-up basis, so prior-period comparisons are not fully comparable.
Key financial metrics
| Metric | FY 2022 |
|---|---|
| Revenue | $717.8 million: Medical $271.7 million; Industrial $446.1 million |
| Gross profit and margin | $310.1 million; 43.2% |
| Operating loss | $297.8 million; operating margin approximately (41.5%) |
| Net loss | $288.4 million; $276.9 million attributable to Mirion stockholders; diluted loss per share $1.53 |
| Adjusted EBITDA | $164.7 million, a non-GAAP measure; approximately 22.9% of revenue |
| Cash from operations | $39.4 million |
| Capital expenditures | $34.6 million in segment disclosures; cash-flow statement reports $34.2 million of purchases of property, equipment and badges |
| Cash and liquidity | $73.5 million cash and equivalents; $480.6 million current assets and $244.3 million current liabilities |
| Debt | $821.7 million outstanding under the senior secured term loan; $824.7 million total third-party borrowings before debt issuance costs. Revolver availability was approximately $80.6 million. |
| Backlog | $737.4 million at year-end; approximately 57% expected to be recognized in 2023 |
The filing reports no separate standalone Q4 financial summary in the supplied text. The company’s reported 2022 results include a $211.8 million goodwill impairment charge and a $37.6 million non-cash gain from the change in fair value of warrant liabilities. Adjusted EBITDA excludes specified items and should not be treated as a GAAP profit or cash-flow measure.
Material changes versus prior periods
- Management compares FY 2022 revenue with an accumulated set of 2021 successor and predecessor periods, reporting a $49.5 million increase; that comparison is affected by the fiscal-year change and is not directly comparable. Medical revenue increased $58.6 million, while Industrial revenue decreased $9.1 million.
- Medical growth reflected acquisitions, price increases and organic growth. Industrial revenue was pressured by project delays related to supply-chain constraints and the Russia-Ukraine conflict, and by foreign exchange; price increases and the SIS acquisition partly offset those effects.
- The company recorded $211.8 million of goodwill impairments: $55.2 million in the Industrial RMS reporting unit following termination of a Russia-related nuclear project, $69.3 million in another Industrial reporting unit, and $87.3 million in a Medical reporting unit.
- Revenue translation was negatively affected by currency movements; management estimated a 4.5% adverse year-over-year impact. The stronger U.S. dollar particularly affected European operations.
- The term-loan interest rate rose to 7.48% at December 31, 2022, from 3.25% at December 31, 2021. The filing estimates that a 100-basis-point increase in market rates would add approximately $8.4 million to annual interest expense, based on year-to-date debt levels.
Outlook, risks and unusual items
- Outlook and liquidity: Management stated that operating cash flow, supplemented by long-term debt arrangements, should provide adequate liquidity for the next 12 months. No numerical revenue or earnings guidance is provided in the supplied filing text. Backlog is not guaranteed revenue: approximately 10%–15% may be unfunded and at risk of cancellation, and customer projects can be delayed or terminated.
- Russia-Ukraine exposure: A terminated Finnish nuclear project removed approximately $67 million from backlog, about 80% of which had been expected to convert to revenue over five years. Russian-related backlog was $100.0 million at year-end. One customer sought recovery of approximately $6 million in advance payments; the company said no advance-payment refunds had been made.
- Costs and execution: Management described continuing pressure from inflation, labor, materials, freight and supply-chain disruptions, including delayed component sourcing and revenue recognition. Fixed-price contracts may expose margins to cost overruns; the filing says about 10% of revenue was associated with fixed-price arrangements without cost-escalation provisions.
- Controls: Management and Deloitte reported ineffective internal control over financial reporting due to a material weakness in IT general controls at a French division, involving program change management and user access. No financial-statement misstatement was identified, but the weakness could prevent or delay detection of a material misstatement. Deloitte’s financial-statement audit opinion was unqualified; its ICFR opinion was adverse.
- Subsequent financing: On February 21, 2023, Mirion issued 17,142,857 shares to T. Rowe Price at $8.75 per share, raising $150 million before fees. The company used $125 million to repay debt and expected to use the remaining $25 million for growth opportunities.
- Other risks: Variable-rate debt, foreign exchange, government-budget cycles, regulatory approvals, product liability, cybersecurity, and acquisition integration may affect results. The company also reported a prior ransomware incident in 2021.
Important facts for investors to verify
- Reconcile the reported revenue and segment trends to comparable calendar-year periods, accounting for the fiscal-year change, business-combination accounting and acquisitions.
- Review the assumptions and sensitivity behind the $211.8 million goodwill impairment and the relatively limited fair-value cushions disclosed for certain reporting units.
- Assess the status and recoverability of the $100.0 million Russia-related backlog, the approximately $6 million advance-payment claim, and related performance obligations and guarantees.
- Confirm current debt, interest-rate exposure, covenant headroom and the effect of the February 2023 $125 million debt repayment; the filing states the company was covenant-compliant at December 31, 2022.
- Track remediation of the French IT-control material weakness and whether controls become effective in subsequent reporting periods.